BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 09:00PM GMT
Release Date Price: $6.74 (+3.53%)
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Good afternoon. We'll continue with the next session. I'm Paul Choi, and I cover the SMid Cap Biotechnology sector here at the firm. And it's my pleasure to welcome BridgeBio for this session. From management joining us is Founder and CEO, Neil Kumar. What we'll do is Q&A. If any audience members along the way have any questions for Neil, please feel free to raise your hand, and we'll try and get a mic to you. But maybe before we start with Q&A, Neil, maybe if you want to provide some any high-level comments that you think are of interest. Otherwise, we can just go into Q&A.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Yes, sure. Happy to. First of all, thanks, everyone, for the time. I think our strategy a bit large over the next 18 months or so is informed by 2 inputs, really, number 1 is our continued belief in our late-stage pipeline of Phase II or Phase III assets in $1 billion-plus markets. And we can talk about those, but those are five

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot